Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis

References

• Anzueto A, Ferguson GT, Feldman G, et al. (2009). Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 6:320–9.
   PubMedGoogle Scholar
• Brassard P, Lowe AM, Bernatsky S, et al. (2009). Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 61:300–4.
   PubMed Web of Science ®Google Scholar
• Brink AJ, Cotton M, Feldman C, et al. (2015). Updated recommendations for the management of upper respiratory tract infections in South Africa. S Afr Med J 105:345–52.
   Web of Science ®Google Scholar
• Calverley P, Anderson J, Celli B. TORCH Investigators (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med 356:775–89.
   PubMed Web of Science ®Google Scholar
• Calverley P, Kuna P, Monsó E, et al. (2010). Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med 104:1858–68.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. (2003). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 361:449–56.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rennard S, Nelson HS, Karpel JP, Abbate EH, Stryszak P, Staudinger H. (2008). One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Resp Res 9:73.
   PubMed Web of Science ®Google Scholar
• Doherty DE, Tashkin DP, Kerwin E, et al. (2012). Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Intl J Chron Obstruct Pulm Dis 7:57–71.
   PubMed Web of Science ®Google Scholar
• Dong Y, Chang C, Lin W, et al. (2014). Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. Chest 145:1286–97.
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Suissa S. (2007). Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176:162–6.
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. (2015). Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 45:525–37.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, et al. (2008). Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Resp Med 102:1099–108.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). (2016). Global strategy for asthma management and prevention. Available from: http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf. [last accessed: Jan 2016].
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2017). Global strategy for the diagnosis, management and prevention of COPD. Available from: http://goldcopd.org. [last accessed: Jan 2017]
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2015). Global strategy for diagnosis, management, and prevention of COPD; NHLBI/WHO workshop report; NIH Publication No. 2701A. Last update 2015.
   Google Scholar
• Hanania NA, Darken P, Horstman D, et al. (2003). The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 124:834–43.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. (2011). The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ 343:5928.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, et al. (2002). Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:1084–91.
   PubMed Web of Science ®Google Scholar
• Ni S, Fu Z, Zhao J, Liu H. (2014). Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. J Thorac Dis 6:971–897.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Plaza V. (2014). Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review. Chest 146:309–17.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Southard JG, Goldman M, et al. (2012). Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 106:257–68.
   PubMed Web of Science ®Google Scholar
• Singh S, Amin A, Loke Y. (2009). Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 169:219–29.
   PubMed Web of Science ®Google Scholar
• Suissa S, McGhan R, Niewoehner D. (2007). Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 4:535–42.
   PubMedGoogle Scholar
• Tashkin D, Doherty D, Kerwin E. (2012a). Efficacy and safety of a fixed-dose combination of mometasonefuroate and formoterolfumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Intl J Chron Obstruct Pulm Dis 7:43–55.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Doherty DE, Kerwin E, et al. (2012b). Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Intl J Chron Obstruct Pulm Dis 7:73–86.
   PubMed Web of Science ®Google Scholar
• van Geffen W, Bruins M, Kerstjens H. (2016). Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study. J Breath Res 10:036001.
   PubMed Web of Science ®Google Scholar
• Wedzicha J, Calverley P, Seemungal T, et al. (2008). The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177:19–26.
   PubMed Web of Science ®Google Scholar
• Zheng JP, Yang L, Wu YM, et al. (2007). The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest 132:1756–63.
   PubMed Web of Science ®Google Scholar